Form 4: Ginkgo Bioworks CFO Plans Future Stock Sale

Ginkgo Bioworks' Chief Financial Officer, Steven P. Coen, reported a planned sale of 5,609 shares of Class A Common Stock for $15 per share, effective October 1, 2025, under a Rule 10b5-1 plan.

Summary

• Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks Holdings, Inc. (DNA), reported a transaction.
• The transaction involves the disposition of 5,609 shares of Class A Common Stock.
• The shares are to be sold at a price of $15 per share.
• The transaction date is scheduled for October 1, 2025.
• Following this planned transaction, Coen will beneficially own 5,503 shares of Class A Common Stock.
• The sale is being conducted pursuant to a Rule 10b5-1 sales plan, adopted by the reporting person.

Sentiment

Score: 5

Explanation: Neutral, as the transaction is a pre-planned sale under a Rule 10b5-1 plan, which typically does not reflect a change in management's outlook on the company's prospects or immediate operational performance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's planned stock transaction.

Industry Context

This specific filing pertains to an individual insider transaction and does not provide broader industry context or trends. Insider sales, particularly those under Rule 10b5-1 plans, are common and do not inherently reflect on the overall health or trends within the biotechnology or synthetic biology industry.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the pre-planned nature of the sale under Rule 10b5-1 generally mitigates concerns about management's confidence in the company.

Key Dates

Recommendation

The sale by the CFO was conducted under a pre-arranged Rule 10b5-1 plan, which typically indicates a planned liquidity event rather than a change in sentiment regarding the company's future prospects. This single transaction does not provide sufficient new information to alter a fundamental investment recommendation.

Keywords

Ginkgo Bioworks, DNA, Steven P. Coen, CFO, Insider Sale, Form 4, 10b5-1 plan, Class A Common Stock